Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development

International Journal of Cancer

Volumn 136, Issue 10, 2015, Pages 2469-2475

  Uriarte, Iker ^a,b   Latasa, M Ujue ^b   Carotti, Simone ^c   Fernandez Barrena, Maite G ^a,b   Garcia Irigoyen, Oihane ^a   Elizalde, Maria ^a   Urtasun, Raquel ^a   Vespasiani Gentilucci, Umberto ^c   Morini, Sergio ^c   De Mingo, Alvaro ^d,e,f   Mari, Montserrat ^d,e,f   Corrales, Fernando J ^a,b   Prieto, Jesus ^a,b   Berasain, Carmen ^a,b   Avila, Matias A ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d INST D INVESTIGACIONS B   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f CSIC   (Spain)

Author keywords

connective tissue growth factor; fibroblast growth factor 15 19; fibrosis

Indexed keywords

ALPHA FETOPROTEIN; CONNECTIVE TISSUE GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR RECEPTOR 4; KLOTHO BETA RECEPTOR; KLOTHO PROTEIN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FIBROGENESIS; GENE EXPRESSION; HEPATITIS; HISTOLOGY; HUMAN; HUMAN CELL; ILEUM; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL; LIVER FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STELLATE CELL; TRANSACTIVATION; TUMOR VOLUME; UPREGULATION; ANIMAL; BLOOD; CELL CULTURE; EXPERIMENTAL LIVER CIRRHOSIS; EXPERIMENTAL LIVER NEOPLASM; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENETICS; HEPG2 CELL LINE; LIVER; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELLS, CULTURED; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKOUT TECHNIQUES; HEP G2 CELLS; HUMANS; ILEUM; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; LIVER NEOPLASMS, EXPERIMENTAL; MICE;

EID: 84924301185     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29287     Document Type: Article

References (25)

1. Hernandez-Gea V, Toffanin S, Friedman SL, et al. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013; 144: 512-27.
2. Lin BC, Desnoyers LR,. FGF19 and cancer. Adv Exp Med Biol 2012; 728: 183-94.
3. Kir S, Kliewer SA, Mangelsdorf DJ,. Roles of FGF19 in liver metabolism. Cold Spring Harbor Symp Quant Biol 2011; 76: 139-44.
4. Ho HK, Pok S, Streit S, et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 2009; 50: 118-27.
5. Sawey ET, Chanrion M, Cai C, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell 2011; 19: 347-58.
6. Miura S, Mitsuhashi N, Shimizu H, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer 2012; 12: 56.
7. Desnoyers LR, Pai R, Ferrando RE, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008; 27: 85-97.
8. French DM, Lin BC, Wang M, et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One 2012; 7: e36713.
9. Nicholes K, Guillet S, Tomlinson E, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002; 160: 2295-307.
10. Uriarte I, Fernández-Barrena MG, Monte MJ, et al. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut 2013; 62: 899-910.
11. Dapito DH, Mencin A, Gwak G-Y, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012; 21: 504-16.
12. Berasain C, García-Trevijano ER, Castillo J, et al. Novel role for amphiregulin in protection from liver injury. J Biol Chem 2005; 280: 19012-20.
13. Park SY, Lee KB, Lee M-J, et al. Nicotinamide inhibits the early stage of carcinogen-induced hepatocarcinogenesis in mice and suppresses human hepatocellular carcinoma cell growth. J Cell Physiol 2012; 227: 899-908.
14. - mice. PLoS One 2010; 5: e15690.
15. Moles A, Tarrats N, Fernández-Checa JC, et al. Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential. Hepatology 2009; 49: 1297-307.
16. Pardo-Saganta A, Pardo-Saganta A, Latasa MU, et al. The epidermal growth factor receptor ligand amphiregulin is a negative regulator of hepatic acute-phase gene expression. J Hepatol 2009; 51: 1010-20.
17. Urtasun R, Latasa MU, Demartis MI, et al. Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology 2011; 54: 2149-58.
18. Gressner OA, Gressner AM,. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int 2008; 28: 1065-79.
19. Latasa MU, Salis F, Urtasun R, et al. Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system. PLoS One 2012; 7: e52711.
20. Huang X, Yang C, Jin C, et al. Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis. Mol Carcinog 2009; 48: 553-62.
21. Takami T, Kaposi-Novak P, Uchida K, et al. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res 2007; 67: 9844-51.
22. Zhang L, Wang Y-D, Chen W-D, et al. Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice. Hepatology 2012; 56: 2336-43.
23. Schaap FG, Trauner M, Jansen PLM,. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 2014; 11: 55-67.
24. Morton GJ, Kaiyala KJ, Foster-Schubert KE, et al. Carbohydrate feeding dissociates the postprandial FGF19 response from circulating bile acid levels in humans. J Clin Endocrinol Metab 2014; 99: E241-5.
25. Ahn S-M, Jang SJ, Shim JH, et al. A genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification. Hepatology, in press.